Week In Review: China Life Science Companies Raise Nearly $1 Billion Led By Legend's $424 Million US IPO

Deals and Financings

  • In a very successful debut offering, Nanjing Legend Biotech priced its US IPO above the expected range at $23 per ADS, raising $424 million. The company's ADS's climbed 60% higher to $36.60 in early trading, giving Legend a market capitalization of nearly $5 billion. Janssen formed a 50-50 partnership with the company for their CAR-T candidate in a $1 billion-plus deal, including $350 million upfront.
  • Everest Medicines, a Shanghai biopharma, announced a very large $310 million Series C round to support clinical trials of its in-licensed candidates. Everest was formed in 2015 with $50 million in initial backing led by China's C-Bridge Capital. 
  • Genor Biopharma, a Shanghai company with ten biologic candidates in clinical trials, completed a $160 million Series B financing led by Beijing's Hillhouse Capital Group.In late 2019, Genor was rumored to be planning a $200 million IPO on the Hong Kong Exchange, but that offering has not been officially announced.
  • Jiangsu Atom Bioscience raised $30 million in a Series B financing that will be used for discovery and development of novel drugs that treat metabolic diseases and cancer. The financing was led by Livzon Pharma and Sequoia Capital China with participation from Kaitai Capital and Fortune Capital. 
  • Deep Informatics++ of Hangzhou, a company that offers AI-based pathology products, completed a Series B financing of over $14 million. Founded in January 2017, Deep Informatics++ uses proprietary AI algorithms to develop multi-module diagnostic tools. Its products include: D-CleverEye (adds AI analysis to a microscope), D-PathAI (AI-assisted pathology diagnosis), and DPathAIS (an AI-based workstation).
  • Beijing Jiushi Shenkang Medical Technology raised nearly $14 million in an A round to develop its portfolio of neuro-interventional medical devices. The company is developing cardio-cerebrovascular interventional medical devices for ischemia and hemorrhagic stroke. The A round was led by Apricot Capital.
  • Jacobio Pharma of Beijing out-licensed rights for its two-molecule SHP2 program to AbbVie (ABBV). Although AbbVie will own exclusive rights to the SHP2 portfolio, Jacobio will conduct early global clinical trials of the molecules, with AbbVie paying R&D expenses. AbbVie will be responsible for global R&D though Jacobio has an option to develop the SHP2 program in greater China.
1 2
View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.